Volume 1.24 | Jun 29

Hematopoiesis News 1.24, June 29, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Depletion of L3MBTL1 Promotes the Erythroid Differentiation of Human Hematopoietic Progenitor Cells: Possible Role in 20q- Polycythemia Vera
To define its role in hematopoiesis, researchers knocked down L3MBTL1 expression in primary hematopoietic stem/progenitor cells isolated from human cord blood (using short hairpin RNAs) and observed an enhanced commitment to and acceleration of erythroid differentiation. [Blood]

Request A Sample  
Column-Free Isolation of
Hematopoietic Stem and Progenitor Cells
with EasySep®


Endoscopic Findings of Cytomegalovirus Gastritis
A research team from Japan demonstrated the endoscopic findings of cytomegalovirus gastritis after allogeneic hematopoietic stem cell transplantation in addition to its clinical features. [Press release from EurekAlert! discussing online prepublication in the World Journal of Gastroenterology]

Researchers Shed Light on Common Juvenile Cancer
A team of researchers have defined for the first time the mechanism behind three cancer-causing genes in acute lymphoblastic leukemia. [Press release from Université de Montréal discussing online prepublication in Genes and Development]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Reconstitution of PTEN Activity by CK2 Inhibitors and Interference with the PI3-K/Akt Cascade Counteract the Anti-Apoptotic Effect of Human Stromal Cells in Chronic Lymphocytic Leukemia
Researchers applied a microenvironment model to explore the interaction between chronic lymphocytic leukemia cells and stromal cells and to elucidate the role of PI3-K/Akt/PTEN cascade in this process and its in vivo relevance. [Blood]

Tropomodulin1-Null Mice Have a Mild Spherocytic Elliptocytosis with Appearance of Tropomodulin3 in Red Blood Cells and Disruption of the Membrane Skeleton
Researchers used a tropomodulin1 (Tmod1) knockout mouse to investigate the in vivo role of Tmod1 in the red blood cell membrane skeleton. [Blood]

Enhanced c-Met Activity Promotes G-CSF Induced Mobilization of Hematopoietic Progenitor Cells Via ROS Signaling
Researchers report that during G-CSF-induced mobilization c-Met expression and signaling are up-regulated on immature bone marrow progenitors. [Blood]

Crotepoxide Chemosensitizes Tumor Cells Through Inhibition of Expression of Proliferation, Invasion, and Angiogenic Proteins Linked to Proinflammatory Pathway
Because nuclear factor kappaB (NF-kappaB) plays a critical role in antitumor and anti-inflammatory signaling pathways, researchers investigated the effects of crotepoxide on NF-kappaB-mediated cellular responses and NF-kappaB-regulated gene products in human cancer cells. [J Biol Chem]

Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520
Researchers studied four multiple myeloma cell lines treated with the kinesin spindle protein inhibitor ARRY-520 to identify factors important for initiating apoptosis while cells are arrested in mitosis. [Mol Cancer Ther]

Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia
Researchers showed that modified human Galectin-9, a lectin that show specific affinity for beta-galactosides, inhibits the proliferation of five chronic myelogenous leukemia-derived cell lines by inducing apoptosis at their IC(50)s from 17.5 to 164.9 nmol/L. [Mol Cancer Res]


Age at Diagnosis and the Utility of Prognostic Testing in Patients with Chronic Lymphocytic Leukemia
The study was undertaken to analyze the survival of chronic lymphocytic leukemia patients relative to age-matched individuals in the general population and determine the age-stratified utility of prognostic testing. [Cancer]

Treatment of Fanconi Anemia Patients using Fludarabine and Low-Dose TBI, Followed by Unrelated Donor Hematopoietic Cell Transplantation
This fludarabine-based regimen facilitates stable engraftment of unrelated PBSCs, but is associated with significant chronic graft vs host disease. [Bone Marrow Transplant]

Retrospective Analysis of Treosulfan-Based Conditioning in Comparison with Standard Conditioning in Patients with Myelodysplastic Syndrome
Here, researchers retrospectively compare the outcome of a treosulfan-based conditioning regimen with standard myeloablative TBI-based conditioning regimens in patients with myelodysplastic syndrome. [Bone Marrow Transplant]

Endoscopic Diagnosis of Cytomegalovirus Gastritis After Allogeneic Hematopoietic Stem Cell Transplantation
The aim of this study was to clarify the endoscopic and clinical findings of cytomegalovirus gastritis after allogeneic hematopoietic stem cell transplantation. [World J Gastroenterol]


Affymax and Takeda Announce Phase III Trials Meet Primary Endpoints for Investigational Drug, Hematide(TM)/Peginesatide, to Treat Anemia in Chronic Renal Failure With Some Differences Noted in Secondary Analyses
Affymax, Inc. and Takeda Global Research & Development Center, Inc., announced preliminary top-line results from the Phase III clinical program for the investigational drug, Hematide(TM)/peginesatide, for the treatment of anemia in chronic renal failure patients. [Affymax, Inc. Press Release]

CIRM Commits $25 Million to Overcome Immune Rejection of Stem Cell Therapies
The Governing Board of the California Institute for Regenerative Medicine, the state stem cell agency created by proposition 71, approved $25 million to fund 19 projects intended to overcome immune rejection of transplanted stem cells. [California Institute for Regenerative Medicine Press Release]

Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg®
Pfizer Inc. announced that based on discussions with the U.S. Food and Drug Administration, it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia) in the United States and that it will be voluntarily withdrawing the new drug application. [Pfizer Inc. Press Release]

ImmunoGen, Inc. Earns Milestone with Start of SAR650984 Clinical Trial
ImmunoGen, Inc. announced that Sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. [ImmunoGen, Inc. Press Release]

Tarix Pharmaceuticals’ TXA127 Receives FDA Orphan Drug Designation for Stem Cell Engraftment
Tarix Pharmaceuticals announced that it’s drug, TXA127, has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. [PR Newswire]


National Heart, Lung, and Blood Institute Funds Research to Improve Safety of Red Blood Cell Transfusions
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is funding nine research grants to determine if the safety and efficacy of red blood cell transfusions vary depending on how long the cells have been stored. [The National Heart, Lung, and Blood Institute Press Release]

NICE Unable to Recommend Cancer Drug in Draft Guidance Owing to Lack of Robust Data
In preliminary draft guidance, a new treatment for patients with a form of leukemia has not been recommended for use in the National Health Service (NHS) because evidence does not yet show how well the drug works compared with current NHS treatment, for the price the NHS is being asked to pay. [The National Institute for Health and Clinical Excellence (NICE), United Kingdom]

NIBIB and the Indian Department of Biotechnology Collaborate to Develop Low-Cost Medical Devices
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) announced the availability of supplemental funding for eligible NIBIB-supported research grants to facilitate collaborative work among researchers in the United States and India.  [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings [National Institutes of Health, United States]

Extension of Expiration Date and Additional Receipt Dates for RFA-AI-10-014: Ancillary Studies in Immunomodulation Clinical Trials (R01) (NOT-AI-10-035)  [National Institutes of Health, United States]

Development of Articles for Rare Diseases [Food and Drug Administration, United States]

July 26-27, 2010: Meeting of the Blood Products Advisory Committee Announcement [Food and Drug Administration, United States]


Translational Cancer Medicine 2010 – USA
July 11-14, 2010
San Francisco, United States

United Kingdom National Stem Cell Network (UKNSCN) Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

The European Molecular Biology Organization (EMBO) Meeting 2010
September 4-7, 2010
Barcelona, Spain

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

Stem Cells and Regeneration
October 3-9, 2010
Woods Hole, United States

American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us